131I標記物介入治療肝癌的臨床研究進展_《中國普外基礎與臨床雜志》

作者：

吳少平綜述 , 盧武勝審校

四川大學華西醫院腫瘤放療科（成都610041）;

關鍵詞：

131I 肝癌栓塞化療內照射治療

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的探討131I標記物介入治療原發性肝癌的臨床價值。方法復習相關文獻，并作綜述性報道。結果131I碘化油（131I LPD）及131I免疫生物制劑均能較好地聚集于肝癌組織，適應證較廣，嚴重的不良反應少見，近期療效肯定，部分臨床試驗證實治療后患者的生存率有提高。結論運用131I標記物介入治療肝癌具有較好的臨床應用前景。

引用本文： 吳少平綜述,盧武勝審校. 131I標記物介入治療肝癌的臨床研究進展. 中國普外基礎與臨床雜志, 2003, 10(5): 513-515. doi: 復制

1.	Liu CL, Fan ST. Nonresectional therapies for hepatocellular carcinoma [J]. Am J Surg, 1997; 173(4)∶358.
2.	Lau WY, Leung TW, Ho SK, et al. Adjuvant intraarterial iodine131labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial [J]. Lancet, 1999; 353(9155)∶797.
3.	de Baere T, Taourel P, Tubiana JM, et al. Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow [J]. Radiology, 1999; 212(3)∶665.
4.	Raoul JL, Bourguet P, Bretagne JF, et al. Hepatic artery injection of I131labeled lipiodol. Part Ⅰ. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases [J]. Radiology, 1988; 168(2)∶541.
5.	Ychou M, Pelegrin A, Faurous P, et al. PhaseI/II radioimmunotherapy study with iodine131labeled antiCEA monoclonal antibody F6 F(ab’)2 in patients with nonresectable liver metastases from colorectal cancer [J]. Int J Cancer, 1998; 75(4)∶615.
6.	隋延仿,何風昌,陳志南.131碘肝癌單克隆抗體Fab片段偶合物體內放射免疫顯像研究 [J]. 中華醫學雜志, 1999; 78(7)∶537.
7.	Novell R, Hilson A, Hobbs K. Ablation of recurrent primary liver cancer using 131Ilipiodol [J]. Postgrad Med J, 1991; 67（786） ∶393.
8.	Ho S,Lau WY,Leung TW, et al. Internal radiation therapy for patients with primary or metastatic hepatic cancer： a review [J]. Cancer, 1998; 83(9)∶1894.
9.	Risse JH,Grunwald F,Strunk H, et al. I131lipiodol therapy in liver neoplasms [J]. Hybridoma, 1999; 18(1)∶83.
10.	Brans B,De Winter F,Defreyne L, et al. The antitumoral activity of neoadjuvant intraarterial 131Ilipiodol treatment for hepatocellular carcinoma： a pilot study [J]. Cancer Biother Radiopharm, 2001; 16(4)∶333.
11.	Partensky C, Sassolas G, Henry L, et al. Intraarterial iodine 131labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study [J]. Arch Surg, 2000; 135(11)∶1298.
12.	Tan SB, Machin D, Cheung YB, et al. Following a trial that stopped early: what next for adjuvant hepatic intraarterial iodine131 lipiodol in resectable hepatocellular carcinoma? [J]. J Chin Oncol. 2002; 20(6)∶1709.
13.	吳英德, 楊克政, 劉由庚, 等.131I抗AFP抗體導向治療肝癌的臨床觀察 [J]. 腫瘤, 1994; 14(4)∶200.
14.	Zeng ZC, Tang ZY, Liu KD, et al. Improved longterm survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131IantiHCC mAb. Phase I/II clinical trials [J]. J Cancer Res Clin Oncol, 1998; 124(5)∶275.
15.	項明，朱上林，林言箴，等.131IHepama1單克隆抗體導向治療肝癌的初步觀察 [J]. 中國腫瘤臨床, 1998； 25(4)∶289.
16.	Abrams RA, Pajak TF, Haulk TL, et al. Survival results among patients with alphafetoproteinpositive,unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center [J]. Cancer J Sci Am, 1998; 4(3)∶178.

1. Liu CL, Fan ST. Nonresectional therapies for hepatocellular carcinoma [J]. Am J Surg, 1997; 173(4)∶358.
2. Lau WY, Leung TW, Ho SK, et al. Adjuvant intraarterial iodine131labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial [J]. Lancet, 1999; 353(9155)∶797.
3. de Baere T, Taourel P, Tubiana JM, et al. Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow [J]. Radiology, 1999; 212(3)∶665.
4. Raoul JL, Bourguet P, Bretagne JF, et al. Hepatic artery injection of I131labeled lipiodol. Part Ⅰ. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases [J]. Radiology, 1988; 168(2)∶541.
5. Ychou M, Pelegrin A, Faurous P, et al. PhaseI/II radioimmunotherapy study with iodine131labeled antiCEA monoclonal antibody F6 F(ab’)2 in patients with nonresectable liver metastases from colorectal cancer [J]. Int J Cancer, 1998; 75(4)∶615.
6. 隋延仿,何風昌,陳志南.131碘肝癌單克隆抗體Fab片段偶合物體內放射免疫顯像研究 [J]. 中華醫學雜志, 1999; 78(7)∶537.
7. Novell R, Hilson A, Hobbs K. Ablation of recurrent primary liver cancer using 131Ilipiodol [J]. Postgrad Med J, 1991; 67（786） ∶393.
8. Ho S,Lau WY,Leung TW, et al. Internal radiation therapy for patients with primary or metastatic hepatic cancer： a review [J]. Cancer, 1998; 83(9)∶1894.
9. Risse JH,Grunwald F,Strunk H, et al. I131lipiodol therapy in liver neoplasms [J]. Hybridoma, 1999; 18(1)∶83.
10. Brans B,De Winter F,Defreyne L, et al. The antitumoral activity of neoadjuvant intraarterial 131Ilipiodol treatment for hepatocellular carcinoma： a pilot study [J]. Cancer Biother Radiopharm, 2001; 16(4)∶333.
11. Partensky C, Sassolas G, Henry L, et al. Intraarterial iodine 131labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study [J]. Arch Surg, 2000; 135(11)∶1298.
12. Tan SB, Machin D, Cheung YB, et al. Following a trial that stopped early: what next for adjuvant hepatic intraarterial iodine131 lipiodol in resectable hepatocellular carcinoma? [J]. J Chin Oncol. 2002; 20(6)∶1709.
13. 吳英德, 楊克政, 劉由庚, 等.131I抗AFP抗體導向治療肝癌的臨床觀察 [J]. 腫瘤, 1994; 14(4)∶200.
14. Zeng ZC, Tang ZY, Liu KD, et al. Improved longterm survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131IantiHCC mAb. Phase I/II clinical trials [J]. J Cancer Res Clin Oncol, 1998; 124(5)∶275.
15. 項明，朱上林，林言箴，等.131IHepama1單克隆抗體導向治療肝癌的初步觀察 [J]. 中國腫瘤臨床, 1998； 25(4)∶289.
16. Abrams RA, Pajak TF, Haulk TL, et al. Survival results among patients with alphafetoproteinpositive,unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center [J]. Cancer J Sci Am, 1998; 4(3)∶178.

《中國普外基礎與臨床雜志》

131I標記物介入治療肝癌的臨床研究進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

131I標記物介入治療肝癌的臨床研究進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料